Resources from the same session
608O - Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)
Presenter: Wungki Park
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA27 - First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients
Presenter: Alberto Montero
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant 608O and LBA27
Presenter: Alexander Drilon
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Slides
Webcast
609O - CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): A phase I study
Presenter: Rui-Hua Xu
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
610O - Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6
Presenter: Manish Patel
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
611O - Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors
Presenter: John Haanen
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant 609O, 610O and 611O
Presenter: Cinta Hierro Carbo
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Webcast